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doi:10.1016/j.ejvs.2010.04.012Abstract Introduction: Telomeres are specialised DNA-protein complexes which cap the
ends of linear chromosomes serving to maintain DNA integrity during cell division. Telomere
length naturally shortens with successive cell divisions and represents a cellular marker of bio-
logical age. This paper aims to provide an overview of telomere biology and review the
evidence for any association between vascular surgical conditions and short telomere length.
Methods: A systematic review of the literature was performed using the search terms ‘telo-
mere’ and ‘vascular’.
Results: Considerable associations between a shorter mean telomere length and coronary
heart disease have been observed. This finding extends to vascular disease risk factors
including age, sex, smoking, obesity, hypertension and diabetes. Vascular diseases including
abdominal aortic aneurysm, peripheral vascular disease and carotid disease were also associ-
ated with shorter telomere lengths but evidence was limited to a small number of studies.
There were no reports of short telomere length associated with varicose veins or arterio-
venous malformations suggesting a novel area for further investigation.
Conclusion: Multiple associations between short telomere length and vascular disease charac-
terised by atherosclerosis suggest a possible link between telomere attrition and disease mech-
anisms. Further studies are warranted to validate and define the role of telomeres in vascular
disease pathogenesis.
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Telomeres are specialised DNA-protein complexes present
at the ends of linear chromosomes in eukaryotes. They
safeguard gene integrity during mitosis by preventing DNA
degradation at chromosomal termini. Telomere length
shortens with each cell division and can be likened to
a ‘mitotic clock’ reflecting cellular turnover. This has given
rise to concepts of telomere length as a surrogate marker of
age at both the cellular level and organism level, as well as
a potential biomarker of age-related diseases. Shortening
of telomeres to a critical length induces ‘replicative
senescence’ e the cessation of mitosis due to a finite
number of cell divisions (the ‘Hayflick limit’). This mecha-
nism appears to prevent genomic instability and develop-
ment of malignancy in aged cells by limiting the number of
cell divisions.1,2 Studies relating to coronary heart disease
have demonstrated short telomere length in peripheral
blood leukocytes to be an independent risk factor for
disease and potentially a superior predictor of disease
onset than chronological age.3,4 Furthermore, correlations
between telomere lengths with specific stages of disease
progression observed in cancer studies have revealed their
potential prognostic and diagnostic value. The aim of this
review was to determine whether this evidence exists for
vascular conditions including aortic aneurysms and carotid
artery disease.
Methods
The Medline and Embase databases were searched from
1965 to October 2009 using the search terms ‘telomere’ and
‘vascular’ and limits ‘English language’ and ‘Human’.
Additional articles were obtained manually from reference
lists and the latest ‘Telomere Biology’ supplement inFigure 1 Literature search flow diagram as per PRISMA guidel
vascular disciplines including haematology and immunology. **LargeNature.5 Articles were screened as per PRISMA guidelines
(Fig. 1).6 Sixty-nine articles were included in the final
qualitative synthesis. Following an overview of telomere
biology, we present salient findings from the literature
under subheadings pertaining to different vascular
conditions.
Telomere biology
Structure and function
Telomeres confer a protective role for each chromosome by
preventing enzymatic erosion, non-homologous recombi-
nation and endeend fusion of chromosomal DNA. Such
events can induce chromosomal instability, apoptosis and
cell death.7 Human telomeres consist of three components,
(i) tandem repeats of guanine-rich non-coding DNA
sequences, predominantly TTAGGG in 50e30 direction, (ii)
shelterin- a complex of six proteins adherent to telomeric
DNA and (iii) telomerase, a DNA polymerase.7e9 Telomeres
are arranged in to duplex loops which comprise a double-
stranded telomere loop (T-loop) and a single-stranded (D-
loop) (Fig. 2).2,8,9 Proteins forming the ‘shelterin complex’
bind to and protect the duplex loop. They prevent false
recognition of telomeres as double-stranded DNA breaks
which would otherwise be vulnerable to aberrant process-
ing by DNA repair complexes.10 The two major shelterin
proteins TRF-1 and TRF-2 (telomere repeat-binding factors)
possess binding domains with high specificity for the telo-
mere-repeat sequences explaining why shelterin is abun-
dant at chromosome ends. TRF-1 is involved in telomeric
DNA remodeling and negative regulation of telomere
length.8 The removal of TRF2 initiates DNA damage repair
pathways which can result in deleterious fusion of chro-
mosomal ends. Human repressor activator protein (hRAP1)
is a binding-partner of TRF2 and can extend telomeresines.6 *Excluded papers included those relevant only to non-
ly reviews that had been expanded upon by more recent work.
Figure 2 The duplex structure of a telomere consisting of
DNA forming a T-loop and D-loop. Several shelterin proteins
bind specifically to the telomeric DNA and facilitate telomere
end protection and length control.2 Shelterin complex core
proteins- TRF1, 2 e Telomeric repeat-binding factors; RAP1-
Human repressor activator protein 1; TIN2 e TRF1einteracting
protein; Accessory Binding proteins- Ku- the Ku70/Ku86 het-
erodimer, tank-1,tank-2- tankyrase; MRE11/RAD50/NBS1-MRN
DNA detection and repair complex, hnRNPs e heterogeneous
nuclear ribonucleoprotein67.
Figure 3 Illustration of the ‘end replication problem’ during
unidirectional DNA replication. 1. Double stranded DNA
‘unzips’ in to a replication fork to allow DNA polymerase to
synthesize in the 50/ 30 direction. 2. Leading strand is
straightforwardly synthesized as continuous DNA from parental
DNA. 3. Lagging strand can only be synthesized in discontinuous
fragments with requirement of a primer. 4. Gap left by primer
removal at the chromosomal terminus (telomere) cannot be
repaired.12
Telomere Length Dynamics in Vascular Disease: A Review 19when overexpressed.11 TRF1-interacting protein 2 (TIN2) is
thought to mediate TRF1 activity and collectively both can
inhibit DNA lengthening by telomerase. The two remaining
shelterin proteins, pot-1 (protection of telomeres) and tpp1
(tripeptidyl peptidase I) are binding partners thought to
both augment and inhibit telomerase function.12 Unlike the
shelterin proteins which constantly reside at the telomere,
numerous non-shelterin accessory proteins are intermit-
tently recruited to the telomere and thought to influence
telomere length control and repression of the DNA damage
response. Examples include tankyrase (tank-1, tank-2)
which may release TRF1 from the telomere and cause DNATable 1 Comparison of telomere attrition (erosion) rates betw
Tissue type
(healthy tissue unless specified)
Attrition rate (mea
base pair loss/year
Vascular tissues
‘Peripheral blood’-cell type
not given26
33
Peripheral blood leukocytes28 31
Iliac arteries intima27 102  13 (SD)
Internal thoracic artery intima 87
Iliac vein endothelium
(non-diseased autopsy specimens)
47  4 (SD)
Myocardium23
(Non-diseased autopsy specimens)
Not given
Non-vascular tissues
Oesophageal mucosa23 60
Thyroid25 91
Parathyroid (normal operative
and autopsy specimens)
92
Large Bowel Mucosa29 (matched
normal mucosa from colorectal
Ca patients-operative specimens)
59
Hepatic30 (non-diseased
autopsy specimens)
55elongation.13 In addition, Ku protein, a heterodimer of 2
polypeptides e Ku70 and Ku80, is integral to the non-
homologous end-joining DNA repair pathway which is
important to telomere maintenance.14 Knockout studies of
the KU86 gene have shown human cell lines to exhibit
higher rates of double-stranded DNA breaks and telomere
loss culminating in cell death.15 Telomerase synthesizes
telomeric DNA and prevents telomere attrition (erosion). Iteen vascular tissues and non-vascular tissue14,16e21.
n
)
n Age ranges
(years)
p-value of
regression
47 20e85 <0.001
123 twins 2e95 <0.005
4 21e58 0.03
4 Not given 0.06
5 14e49 Not given
168 0e104 0.17
177 0e102 Not given
46 0e98 <0.0001
21 0e83 <0.0001
129 0e9 <0.0001
94 0e101 <0.0001
20 H.Z. Butt et al.is integral to telomere maintenance and regulates cellular
lifespan.16 Whilst absent in most somatic cells, low levels
exist in highly proliferative cell lines including skin and
intestinal mucosa.1,17 Conversely, telomerase expression is
upregulated in germline, embryonic and stem cells and
more so in human cancer cells, contributing to cell
immortalisation.16e18 Telomerase is composed of an RNA
component (TERC) which serves as a template for DNA
synthesis and a reverse transcriptase (TERT) which catal-
yses the elongation.17 Mutations and overexpression of
these subunits may have pathological implications having
been observed in conditions involving stem-cell failure,
idiopathic pulmonary fibrosis and carcinogenesis.19
Telomere length and assessment
Each round of DNA replication results in a shorter telomere
by 30e100 nucleotides.12 This is consequential of the ‘end
replication problem’ that arises from the inability of DNA
polymerase to replicate the 50 end of the lagging strand
after degradation of an RNA primer (Fig. 3).20 This loss of
telomeric DNA can be regenerated by telomerase. Human
telomere length varies between tissues from 12 to 16 kilo-
base (kb) pairs in comparison to 20e50 in mice.8,14,21 It may
vary between chromosomes belonging to the same cell and
between individuals of the same age.22,23 During intra-
uterine life till birth however, telomere length appears to
be consistent between leukocytes, liver, lung, muscle and
myocardium.22e24 Loss of this synchrony in adulthood may
be attributable to variable cellular proliferation rates as
one matures. Indeed, it is evident that the rate of telomere
attrition varies in different tissues, and accounts for
30e150 bp loss per annum (Table 1).21e23,25e30 Strong
associations observed between peripheral blood leukocyte
(PBL) telomere length in fathers and their children, may
suggest paternal inheritance.31 Women’s telomeres have
been reported to be 3.5% longer than men’s after adjust-
ment for age in one study (n Z 143).32 Despite similar PBL
telomere lengths in newborn males and females, age-
dependent telomere attrition occurs at a higher rate in
males.23 However, beyond the age of 60 there is no such
difference and women maintain longer telomeres into old
age.33 However, others could not replicate these gender
differences in PBL telomere length in elderly cohorts (79
years).24,27 Telomere length is thus far considered an
emerging marker of cellular ageing and age-related disease
and has been measured by an array of techniques, most
commonly by Southern Blot analysis of terminal restriction
fragments (TRF). Other techniques including hybridization
protection assays and fluorescence in situ hybridization are
gaining popularity (Table 2).8 Evidence of shortened tissue
telomere length patterns observed in both malignant and
benign diseases including colorectal carcinoma, colonic
polyps and gastric adenomas have revealed their potential
value as biomarkers.26,34,35
Telomere length and aortic disease
Latest telomere studies suggest that biological ageing of
the vasculature may play a role in abdominal aortic
aneurysm aetiology. We implemented the Southern Blot
technique to compare peripheral blood leukocyte (PBL)telomere length in abdominal aortic aneurysms (n Z 190)
with that in age-sex matched controls (n Z 183).36,37
Significantly shorter telomere length was detected in
AAA, evident by a mean difference of 189 bp (95% CI 77
bp-301 bp, P Z 0.005). This relationship persisted after
controlling for confounding risk factors with multiple
regression analysis. Individuals in the lowest quartile of
mean telomere length exhibited a 2-fold risk of AAA
relative to those with a mean telomere length in the
highest quartile (odds ratio 2.30, 95% CI 1.28e4.13,
PZ 0.005). Secondly, our data demonstrated a significant
negative correlation between AAA diameter and telomere
length. Previously, Wilson et al. compared PBL ‘telomere
content’ from AAA (nZ 20, nZ 12 controls) in a separate
cohort of patients by qPCR.38 Significantly reduced telo-
mere content was apparent in AAA against controls (0.82,
SD 0.06 and 1.27, SD 0.10 respectively, p < 0.001). The
mean telomere content of aneurysm wall biopsies was
compared in these cases (obtained during elective AAA
repair) with unmatched controls (normal cadaveric aorta).
Telomeric DNA was reduced in AAA vs. controls after
adjusting for age and gender (2.17, 95% CI 1.77e2.56 vs.
2.80, 95% CI 2.32e3.28, P < 0.05). Furthermore, signifi-
cant positive correlation of PBL telomere content with
tissue telomere content was apparent for both cases and
controls (partial correlation coefficient 0.62, P < 0.001).
This correlation suggests that such PBL telomere
measurements hold potential as accessible markers of
vascular ageing in the aorta, in individuals with or without
aneurysmal disease. Earlier, Okuda et al. assessed the
telomere length in biopsies from non-aneurysmal aorta
against the severity of any atherosclerotic lesions present
(n Z 44).39 Although telomere length in distal aortic
biopsies shortened as atherosclerotic grade increased,
this association was not significant after adjustment for
age (p Z 0.06). The group did demonstrate however,
a significantly higher rate of age-dependent telomere
attrition in proximal aorta in comparison to distal aorta
(intima pZ 0.003, media pZ 0.004). Although there is no
obvious explanation for this, the authors suggest that
local factors such as shear wall stress may influence such
findings.
Peripheral arterial disease and venous disease
Leukocyte telomere length has been measured in patients
with chronic heart failure, with or without other athero-
sclerotic manifestations including peripheral vascular
disease (age 40e80, cases n Z 620, controls n Z 183).40
The presence or past history of peripheral vascular
disease (PVD), defined as ‘claudication’, was an indepen-
dent predictor of a short telomere length (age-adjusted
regression, p Z 0.001). The ambiguous definition of PVD
however, requires cautious interpretation of results. These
findings failed to be replicated by the prospective Cardio-
vascular Health Study (age >65, n Z 419), where PVD was
defined as an ABPI of <0.9.41 Twenty-two cases of PVD were
identified (7.9 year follow-up) and did not correlate with
a shorter leukocyte telomere length (p Z 0.51). Zee et al.
have conducted the only telomere study in venous
disease.42 Leukocyte telomere length in men whom
Table 2 Summary of telomere measurement techniques in practice.
Technique Principles Merits Limitations
Southern Blot
analysis of terminal
restriction
fragments8
Genomic DNA is digested by restriction enzymes in to
fragments which are separated by electrophoresis.
These are hybridized to labelled probes specific for
telomere sequences. The hybridized terminal restriction
fragments are quantified by densitometry and reflect an
approximation of telomere length
Universal standard of comparison to
newer methods
Provides mean telomere length of
all chromosomes
Overestimates telomere length since
includes subtelomeric sequences of
unknown length
Labour intensive (w5 days)
Requires pure unfragmented input DNA
Radiolabelling procedures unavoidable
Hybridization
protection assays68
Oligonucleotide probes labelled with a highly
chemiluminescent acridinium ester specifically
bind to telomere sequences. Resultant
luminometer readings allow quantification of
telomere repeats
Mean telomere length obtained without
including subtelomeric regions-more
accurate than Southern blotting
Less stringent input DNA purity required
Expedient protocols (<1 h)
Radiolabelling procedures not required
Provides limited detail of telomere length
at the chromosomal or cellular level
Fluorescence in situ
hybridization
(FISH)69
Telomere repeat-specific peptide nucleic acid probes
labelled with fluorescent dye emit signals quantifiable
by digital imaging systems. Small sized probes allow
effective cellular penetration
Allows precise telomere repeat number
quantification in individual cells
Viable cells from culture required but only
<30. Enhanced precision variants available
e.g. quantitative-FISH
Labour intensive
High requirement for technical expertise
Flow cytometry
FISH e ‘Flow-FISH’21
FISH is supplemented by use of antibody staining i.e. 2
probes, which allows targeting of specific cell lines
within a sample
Telomere length determination possible in
single cells
High sensitivity, accuracy and
reproducibility due to use of 2 probes
Moderate/high complexity protocols
w30 h protocol
Large number of cells required
Quantitative-
polymerase
chain reaction
(qPCR)8
Oligonucleotide primers specifically anneal to telomere
repeat sequences and allow amplification and
quantification in a thermal cycler. Comparison to a
single reference gene allow telomere length to be
expressed as telomere repeat copy number/single gene
copy number ratio
More rapid than Southern Blot and
requires less input DNA
Multiplex high-throughput e.g. 384-well
format protocols available e suitable for
epidemiological studies
Provides a relative reading of telomere
length as opposed to absolute telomere
length e therefore difficulty comparing to
other methods
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22 H.Z. Butt et al.incidentally developed venous-thromboembolism (nZ 108,
DVT 60%, PE 40%) were compared with ageesex matched
controls (n Z 108). No significant difference in telomere
length was detected between cases and controls
(p Z 0.62).
Telomeres and carotid disease
The Cardiovascular Health Study conducted ultrasound
measurements of common carotid and internal carotid
intima-media thickness (n Z 419).41 Although shorter
leukocyte telomere length was observed with increasing
carotid stenosis, this failed to reach significance
(p Z 0.07). Benetos et al. compared leukocyte telomere
length against incidence of carotid plaques in an exclu-
sively hypertensive cohort (n Z 163).43 Carotid plaques
were detected by ultrasound in 73 patients (44%), whom
collectively exhibited a significantly shorter telomere
length than those without plaques (n Z 90 controls,
8.21 kb vs. 8.43 kb, p Z 0.03). There was no difference in
mean lipid levels (HDL, LDL, total cholesterol) between the
two groups and statistical significance remained after
excluding fifty-five patients on lipid-reducing drugs. This
suggests that a shorter leukocyte telomere length may be
a superior predictor of carotid plaque development in
hypertensive patients and questions the role of telomeres
in plaque pathogenesis. Subsequently, Adaikalakoteswari
et al. compared leukocyte telomere length in type-2 dia-
betics with (nZ 30) or without evidence of carotid plaques
and femoral plaques on ultrasound (n Z 30).44 Telomere
length was shorter in diabetics with plaques (5.39, SEM
0.2 kb) compared to those without (6.21, SEM 0.2 kb) and
collectively these were significantly shorter than those of
non-diabetic controls (8.7, SEM 0.5 kb). However, they
have failed to specify what proportion of the group of
‘diabetics with plaques’ had either femoral or carotid
plaques.Telomeres and vascular risk factors
Hypertension and pulse pressure
In the Framingham Heart Study, hypertensive male subjects
(n Z 171) exhibited significantly shorter age-adjusted
leukocyte telomere length compared with their normo-
tensive peers (nZ 156).45 The Cardiovascular Health Study
however, could not replicate this in a mixed male and
female cohort (p Z 0.82).41 Arterial pulse pressure widens
with age since systolic pressure gradually rises and diastolic
pressure plateaus. This prompted Jeanclos et al. to
hypothesize that pulse pressure may represent a phenotype
of biological age. They investigated leukocyte telomere
length against pulse pressures in a twin population (nZ 98
pairs).46 Significant inverse correlation of telomere length
with pulse pressure was noted, suggesting those with
shorter telomeres exhibit a wider pulse pressure
(pZ 0.0032). Two studies suggest that telomere shortening
may occur in arterial segments susceptible to increased
hemodynamic stress. Okuda et al. identified a higher telo-
mere attrition rate in infrarenal aortic specimens relativeto the proximal abdominal aorta (n Z 51 matched biop-
sies).39 In addition, Chang and Harley showed iliac artery
endothelial cells have shorter telomeres than those in
internal thoracic arteries (n Z 13 matched biopsies).27
These data collectively imply that shorter telomere
length, associated with increased endothelial cell turnover,
may be a consequence of higher shear stresses in the
vasculature. Replacement of functional cells with sen-
escent endothelial cells, a process accelerated by exposure
to reactive oxygen species, has been implicated in the
pathogenesis of atherosclerosis.27,45,47
Smoking, obesity and diabetes
Valdes et al. reported that the mean leukocyte telomere
length of obese women (BMI  30, nZ 119) was found to be
240 bp shorter than in lean women (BMI  20, n Z 85,
pZ 0.026).48 In turn, a cohort study of both sexes (nZ 70,
57% female) demonstrated annual leukocyte telomere
length to significantly fall in those with an increasing BMI,
independent of age over a 10-year period (p  0.001).49
Valdes et al. demonstrated a dose-dependent relationship
between leukocyte telomere shortening and smoking.48
Each pack-year smoked equated to loss of an additional
5 bp (18%) of the average yearly loss in age-adjusted telo-
mere length. The dose-dependent effects of smoking were
replicated by Morla et al. in a cohort of male smokers with
and without COPD (50 smokers, 26 ‘never-smokers’).50
Telomere shortening correlated with cumulative exposure
to tobacco, independent of concomitant COPD. These
results may collectively implicate smoking and obesity with
pro-ageing effects. However, these findings were not
reproduced by two studies of elderly individuals which
failed to correlate shorter telomeres with number of ciga-
rettes smoked per day or total number of cigarettes
smoked.51,52 The mean ages of each cohort were consid-
erably higher in these studies, at 81 (n Z 812) and 79
(n Z 598). Recent evidence of telomere instability in
individuals over 85 years old may explain the discrepancies
between these studies with dissimilar demographics.52
Studies on South Asian populations have shown shorter
leukocyte telomere lengths in individuals affected by non-
insulin dependent diabetes (NIDDM, n Z 40) and impaired
glucose tolerance (n Z 30) compared to controls
(n Z 40).44,53 Jeanclos et al. previously demonstrated the
same findings for insulin dependent diabetes mellitus
(IDDM) but not for NIDDM in Caucasian men (n Z 54 vs.
n Z 106 controls).54 Others have shown association
between short leukocyte telomeres and diabetes, fasting
insulin and fasting glucose and higher attrition rates in
increasing insulin resistance.41,45,49 Conversely, Sampson
et al. could only demonstrate shorter telomere length
specifically in monocytes, not lymphocytes, in those with
NIDDM (n Z 21) against controls (n Z 29).55
Telomeres and coronary heart disease
Several studies have described short telomere length to
carry predictive value for coronary heart disease (CHD)
onset and CHD-specific mortality. The largest prospective
study amongst these included that of Brouilette et al.
Table 3 Summary of telomere length dynamic studies in vascular surgical disease and healthy vascular tissue.
Condition/tissue Telomere
source
Telomere
measurement
Main findings cases/controls P-value Reference
AAA Leukocytes TRF*-Southern Blot
analysis
Reduced telomere length in AAA
Telomere shortening correlated with
increasing AAA diameter
190/183 0.005 Atturu et al.36,37
Leukocytes Telomere/genomic
DNA ratio e qPCR
Reduced telomere content in AAA 20/12 <0.001 Wilson et al.38
AAA proximal
sac vs. healthy
aorta
Telomere shortening in AAA 20/12 <0.05
Atherosclerotic
non-aneurysmal
aorta
Matched aortic
intimal and
medial biopsies
TRF e Southern Blot
analysis
Increased telomere attrition rate in
distal aorta vs. proximal aorta for
both tunica intima and tunica media
44/44 0.003 Okuda et al.39
Peripheral vascular
disease (PVD)
Leukocytes Telomere to single
reference gene (T/S)
ratio e qPCR
Reduced telomere length in patients
with chronic heart failure and
claudication vs. those without
claudication
620/183 0.001 Van Der Haarst
et al.40
Leukocytes TRF e Southern Blot
analysis
No association between telomere
length and PVD -ABPI <0.9
22/n/a 0.51 Fitzpatrick
et al.41
Carotid disease Leukocytes TRF e Southern Blot
analysis
Reduced telomere length in
hypertensives with carotid plaques
vs. those without plaques
73/90 0.03 Benetos et al.43
Leukocytes TRF e Southern Blot
analysis
Reduced telomere length in type 2
diabetics with carotid and femoral
plaques vs. those without plaques
30/30 0.0001 Adaikalakoteswari
et al.44
*TRFe terminal restriction fragment.
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24 H.Z. Butt et al.whom detected shorter leukocyte telomere lengths in
patients whom developed CHD compared to controls in
a 4.9-year follow-up study (cases 484, controls 1058).3 The
risk of developing CHD was doubled in patients with telo-
mere lengths in the middle and lowest tertiles. Brouilette
et al. had previously shown that telomere length in the
lowest 2 quartiles carried at least a 2-fold risk of developing
premature MI (203 cases, 180 controls).56 A prospective
study following healthy individuals aged 60e97 years
assessed the impact of baseline leukocyte telomere length
on subsequent cause-specific mortality (n Z 143).32 Indi-
viduals in the lower half of telomere length distribution
displayed a 3.18-fold higher risk of CHD-specific mortality
than those in the higher distribution. Comparable results
have arisen from a ten-year prospective analysis of 419
individuals (aged  73).41 This revealed a 3-fold risk of
myocardial infarction in those with shorter telomeres. Most
recently (2008), replication of these results has been ach-
ieved by a larger prospective case-control study (337 cases,
337 controls), limited however, to an entirely male
cohort.57 Starr et al. recruited 190 participants and found
PBL telomere lengths were significantly shorter in patients
symptomatic of CHD (nZ 63) and those with ischaemic ECG
changes (n Z 75).58 Telomere length studies in coronary
endothelium have been limited due to difficulty obtaining
sufficient DNA from inherently small target vessels.
However, Ogami et al. were able to compare telomeric DNA
content in diseased coronary arteries (n Z 11) against
normal arteries from autopsy specimens (n Z 22). Signifi-
cantly lower telomere content existed in the group with
diseased arteries.59
Discussion
Multiple studies support an association between short telo-
mere length and increased predisposition to cardiovascular
morbidity including myocardial infarction and hypertension.
This association extends to vascular risk factors including
obesity, smoking and diabetes. However, only a small sub-set
of studies show direct-association with vascular surgical
conditions such as aortic aneurysm, carotid stenosis and PVD
(Table 3). The few studies contesting such associations
involved exclusively elderly cohorts (>85 years). An expla-
nation for the latter negative findings may include that
telomere attrition may increase vascular disease risk up to
a certain point, beyond which other risk factors including
chronological age may invoke a greater additional risk.43
Aside from one study relating to venous thromboembolism,
there were no telomere studies of venous disorders such as
varicose veins and arterio-venous malformations suggesting
a novel area for further investigation. Overall, the associa-
tions reported above suggest that premature vascular ageing
and associated disease may potentially be discernable by
a shorter telomere length. There remains insufficient
evidence however, to validate this association and deter-
minewhether short telomeres are a cause or consequence of
disease. Cellular senescence being a major feature of
atherosclerotic plaques, lends support to the hypothesis that
shorter telomeres may be linked to conditions characterised
by atherosclerosis.60 Evidence of short telomeres with
differential expression of senescence-associated markers
exists in vascular smooth muscle cells (VSMC) derived fromatherosclerotic plaque specimens compared to normal
VSMC.61 Accelerated replacement of healthy tissue with
senescent tissue may link telomere attrition to disease
development since the senescent phenotype has been linked
to endothelial dysfunction and plaque instability.60,62 Other
proposed mechanisms linking telomere attrition to vascular
disease include; (1) oxidative DNA damage e particularly in
the presence of smoking and hypertension (known states of
high oxidative stress); (2) telomere attrition due to higher
rates of leukocyte proliferation as part of a global inflam-
matory response accompanying atherosclerotic disease; (3)
reduced telomerase activity; and (4) association of short
leukocyte telomere length with elevated plasma homo-
cysteine (a risk factor for vascular disease).60,62e65 Accu-
rate delineation of true changes in telomere length will
require prospective longitudinal studies where serial
measurements are scaled against incidence and progres-
sion of vascular disease over time e.g. AAA incidence and
rate of expansion. This requires standardised outcome
measures of vascular morbidity such as objective angio-
graphic evidence of PVD as opposed to subjective reports
of claudication symptoms in previous studies. One such
study in progress is the Asklepios Study, a population study
prospectively monitoring leukocyte telomere length and
onset of cardiovascular events in a disease-free cohort
(n Z 2524).66 Outcome measures of interest to vascular
surgeons include detection of phenotypes including carotid
and femoral stenosis as well as haemodynamic measures of
vascular function. The non-specific modulation of telomere
length by a multitude of modifiable and non-modifiable
risk factors such as age, gender, smoking and obesity
however, suggest a poor specificity and limited potential
as a biomarker of disease.
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